AtomVie Global Radiopharma Inc. ("AtomVie"), incorporated in late 2021, is a global leading CDMO for the GMP manufacturing and distribution of clinical and commercial radiopharmaceuticals and the most recent spinout from the Centre for Probe Development and Commercialization (CPDC). AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of your radiopharmaceuticals from Phase 1 to the commercial marketplace. With a state-of-the art purpose-built facility that will be operational in Q4 2025, AtomVie empowers the development of your radiotherapeutics. For more information about AtomVie, visit our website or contact: info@atomvie.com.
Company Details
- Employees
- 137
- Address
- 1280 Main St W, Hamilton,ontario L8s 4k1,canada
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.atomvie.com/
- HQ
- Hamilton, Ontario
Atomvie Global Radiopharma Inc. Questions
Atomvie Global Radiopharma Inc.'s website is https://www.atomvie.com/
Atomvie Global Radiopharma Inc.'s LinkedIn profile is https://ca.linkedin.com/company/atomvie
Atomvie Global Radiopharma Inc. has
137 employees.
View email and phone details for 137
employees at Atomvie Global Radiopharma Inc..
Atomvie Global Radiopharma Inc.'s industry is
Pharmaceutical Manufacturing
Atomvie Global Radiopharma Inc.'s top competitors are
Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company,
Bora Pharmaceuticals,
Apotex Inc.,
Omniabio,
Ccrm,
Cpdc (Centre For Probe Development And Commercialization),
Nucleus Radiopharma,
Fusion Pharmaceuticals,
Sanofi,
Novocol Pharma, A Septodont Company.
Atomvie Global Radiopharma Inc.'s categories are Pharmaceutical Manufacturing
